肺癌EGFR基因突变以及靶向药物耐药机制的研究进展

钱璐; 边莉

肺癌EGFR基因突变以及靶向药物耐药机制的研究进展

钱璐,
边莉

昆明医科大学第一附属医院病理科

基金项目:

基金：国家自然科学基金资助项目 (81460355);

计量
- 文章访问数: 3517
- HTML全文浏览量: 1304
- PDF下载量: 270
- 被引次数: 0
出版历程
- 收稿日期: 2017-05-14

Research Progress of EGFR Mutations in Lung Cancer and Targeted Drug Resistance Mechanisms

Qian Lu ,
Bian Li

Funds:

基金：国家自然科学基金资助项目 (81460355);

摘要

摘要: EGFR基因突变与肺癌发生发展密切相关, 介绍不同EGFR基因突变类型对靶向药物TKI的敏感性以及回顾靶向药物耐药机制的研究进展, 进一步指导临床靶向用药.
- 表皮生长因子受体 /
- 非小细胞肺癌 /
- 酪氨酸激酶抑制剂
Abstract: EGFR mutations are closely associated with lung cancer development, this paper introduces the effectiveness of tyrosine kinase inhibitors on different epidermal growth factor receptor mutations and reviews the research progress of targeted drug resistance mechanisms, the aim is to further guide clinical targeted drugs.
- Epidermal growth factor receptor /
- Non-small cell lung cancer /
- Tyrosine kinase inhibitors

HTML全文

参考文献(15)

[1]	[1]FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al.Cancer incidence and mortality worldwide:Sources, methods and major patterns in GLOBOCAN 2012[J].Int J Cancer, 2015, 136 (5) :359-386.
[2]周清华, 孙燕.加强我国肺癌分子靶向治疗基础和临床研究[J].中国肺癌杂志, 2004, 7 (4) :267-269.
[3]	[3]BALAK M N, GONG Y, RIELY G J, et al.Novel d761y and common secondary t790m mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors[J].Clin Cancer Res, 2006, 12 (21) :6494-6501.
[4]	[4]CHIU C H, YANG C T, SHIH J Y, et al.Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I Mutations[J].Journal of Thoracic Oncology, 2015, 10 (5) :796-797.
[5]	[5]KANCHA R K, VON BUBNOFF N, PESCHEL C, et al.Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy[J].Clin Cancer Res, 2009, 15 (2) :460-467.
[6]	[6]ROBERTS P J, STINCHCOMBE T E, DER C J.Personalized medicine in non small cell lung cancer:is KRAS a useful maker in selecting patients for epidemal growth factor receptor targeted therapy[J].Clin Oncol, 2010, 14 (20) :69-77.
[7]	[7]HELLMAN M D, REVA B, YU H, RUSCH V, et al.Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib[J].Journal of Thoracic Oncology, 2014, 10 (9) :73-74.
[8]	[8]AKITOHATA M D, HIROSHIGE YOSHIOKA M D, SHIRO FUJITA, et al.Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer[J].Journal of Thoracic Oncology, 2010, 10 (5) :1524-1528.
[9]	[9]JENN-YU W U, CHONG-JEN Y U, YEUN-CHUNG CHANG, et al.Effectiveness of Tyrosine Kinase Inhibitors on"Uncommon"Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non-Small Cell Lung Cancer[J].Clin Cancer Res, 2011, 17 (11) :3812-3821.
[10]	[10]WU Y L, LEE J S, THONGPRASERT S, et al.Intercalated combination of chemotherapy and erlotinib for patients with Advanced stage non-small-cell lung cancer (FASTACT-2) :A randomised, double-blind trial[J].Lancet Oncol, 2013, 14 (8) :1-10.
[11]李静, 武新虎, 刘志冰, 等.阿法替尼联合西妥昔单抗治疗非小细胞肺癌EGFR T790M突变所致的吉非替尼耐药[J].肿瘤, 2013, 33 (7) :619.
[12]	[12]BUTTS C A, BODKIN D, MIDDLEMN E L, et al.Randomized phase II study of gemcitabine plus cisplatin with or without cetuximab, as first-line therapy for patients with advanced or metastatic non-small-cell lung cancer[J].J Clin Oncol, 2007, 25 (36) :5777-5784.
[13]	[13]ROSELL R, ROBINET G, SZCZESNA A, et al.Randomized phaseⅡsutdy of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer[J].Ann Oncol, 2008, 19 (2) :362-369.
[14]	[14]KIM E S, NEUBAUER M, COHN A, et al.Docetaxel or pemetrexed with or Without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy:A phase3, open-label, Randomised trial[J].Lancet Oncol, 2013, 14 (13) :1326-1336.
[15]	[15]KOBAYASHI S, JI H, YUZA Y, et al.An alternative inhibitor overcomes esistance caused by a mutation of the epidemal growth factor receptor[J].Cancer Res, 2005, 65 (16) :7096-7001.

相关文章(20)

[1]	杨升锡, 朱加德, 李秋睿, 屠文莲. 阿美替尼对比奥希替尼治疗EGFR突变晚期NSCLC的临床疗效研究, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20250510
[2]	徐益多, 周彦琪, 王健, 龙江. S100A9-RAGE/TLR4信号轴调控非小细胞肺癌脑转移和内皮黏附的作用, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20250903
[3]	李盈甫, 郭妮, 罗正光, 邢安灏, 李太福, 马千里. EGFR基因多态性与云南汉族人群非小细胞肺癌的关联性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20250413
[4]	余会敏, 辛鑫, 梁志伟. KIAA1199基因和Linc00673基因对非小细胞肺癌化疗疗效的预测价值分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20250115
[5]	姚月婷, 李帅, 曹杨, 林牧, 罗正光, 陈小波, 马千里. 表皮生长因子基因遗传多态性与非小细胞肺癌的相关性研究, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20250910
[6]	张彩妮, 李娅. 卡瑞利珠联合化疗治疗非小细胞肺癌的有效性及安全性Meta分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240610
[7]	洪超, 向旭东, 李盈甫, 曹杨, 陈雪雅, 李帅, 邢安灏, 林牧, 马千里. ERK1/2信号通路基因3'UTR多态性与非小细胞肺癌的相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240302
[8]	梁燕, 王磊, 雷鸣, 陈本超, 孙萍, 李帅, 刘莉, 王倩蓉, 廖曼霖, 马千里. KRAS基因多态性与云南汉族人群非小细胞肺癌的相关性分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230210
[9]	李春桃, 张雪梅, 苏琰迪, 张剑青. 过表达及敲减LncRNA RP11-521C20.3的非小细胞肺癌A549稳转细胞株的构建, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20231016
[10]	吴茂芳, 周永春, 蔡静静, 莫欣, 李瑛玮, 毛佳惠. 云南地区多结节肺腺癌EGFR突变及其临床意义, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220215
[11]	杨佳, 李娅娴, 王莹莹, 肖琳, 李传印, 谭芳, 马千里, 刘舒媛. 云南汉族人群mircoRNA-149、mircoRNA-219、mircoRNA-let-7基因多态性与非小细胞肺癌发生和发展的相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20211037
[12]	王应霞, 何琴, 王国芳, 张旋. 非小细胞肺癌中microRNA-21和EGFR的表达及意义, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210818
[13]	马晓骉, 罗峰, 高永亮, 郝静超. CIK细胞免疫疗法联合化疗治疗非小细胞肺癌的临床疗效, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20201215
[14]	陈本超, 李恒, 刘超, 王书廷, 李高峰. G蛋白偶联受体激酶5与非小细胞肺癌的临床相关性, 昆明医科大学学报.
[15]	王娟, 苏国苗, 潘国庆, 边莉, 杨哲, 曾定涛. 云南地区非小细胞肺癌EGFR、ALK和ROS1基因突变联合检测, 昆明医科大学学报.
[16]	唐诗聪, 潘泓, 黄耀元, 周鑫, 王守峰, 左传田, 茅乃权. 人非小细胞肺癌裸鼠移植瘤模型的建立, 昆明医科大学学报.
[17]	钟芳芳. 运用ARMS法检测非小细胞肺癌表皮生长因子受体基因突变, 昆明医科大学学报.
[18]	周喆焱. E-cadherin对非小细胞肺癌的转移和靶向治疗的影响, 昆明医科大学学报.
[19]	杨芳. 两种不同形式的TNF相关凋亡诱导配体对非小细胞肺癌作用的研究, 昆明医科大学学报.
[20]	张兰凤. 易瑞沙治疗晚期非小细胞肺癌的临床观察, 昆明医科大学学报.